SPONSOR
Chinese PLA General Hospital
Total Trials
15
Recruiting
15
Phases
Phase 2, Phase 1, Phase 1, Phase 2, Phase 4
Conditions studied: Pulmonary DiseaseDiabetic Kidney Disease (DKD)EBV Infection After Allogenic HSCTHER2 Positive Advanced Solid TumorsHepatocellular Carcinoma Stage IIIAcute Lymphocytic LeukemiaHodgkin's LymphomaNon-Hodgkin's LymphomaDiabetic NephropathyT2DM
Chinese PLA General Hospital is a clinical research sponsor with 15 registered studies on ClinicalTrials.gov, of which 15 are actively recruiting participants. Research covers conditions including Pulmonary Disease, Diabetic Kidney Disease (DKD), EBV Infection After Allogenic HSCT, HER2 Positive Advanced Solid Tumors.
The trial portfolio spans Phase 2, Phase 1, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Chinese PLA General Hospital
How many clinical trials has Chinese PLA General Hospital sponsored?
ClinicalMetric currently tracks 15 clinical trials sponsored by Chinese PLA General Hospital, of which 15 are actively recruiting participants. These trials cover conditions including Pulmonary Disease, Diabetic Kidney Disease (DKD), EBV Infection After Allogenic HSCT. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Chinese PLA General Hospital research focus on?
Chinese PLA General Hospital clinical trials span Pulmonary Disease, Diabetic Kidney Disease (DKD), EBV Infection After Allogenic HSCT, HER2 Positive Advanced Solid Tumors, Hepatocellular Carcinoma Stage III, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Chinese PLA General Hospital clinical trial?
To participate in a Chinese PLA General Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Chinese PLA General Hospital trials with current recruitment status updated daily.
Clinical Trials by Chinese PLA General Hospital
NCT04441151
Recruiting
Evaluation of the Effect of Pulmonary Rehabilitation on Patients With High Flow Oxygen Therapy
Pulmonary Disease
NCT06969807 Phase 2
Recruiting
Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease
Diabetic Kidney Disease (DKD)
NCT06119256 Phase 1
Recruiting
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
EBV Infection After Allogenic HSCT
NCT05681650 Phase 1, Phase 2
Recruiting
HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
HER2 Positive Advanced Solid Tumors
NCT06559761
Recruiting
Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research
Hepatocellular Carcinoma Stage III
NCT06481735 Phase 1, Phase 2
Recruiting
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Acute Lymphocytic Leukemia
NCT02259556 Phase 1, Phase 2
Recruiting
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Hodgkin's Lymphoma
NCT06843304
Recruiting
The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy
Diabetic Nephropathy
NCT07101588 Phase 4
Recruiting
Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
NCT06462742
Recruiting
Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma
Overall Survival
NCT06014073 Phase 1, Phase 2
Recruiting
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
Non Hodgkin's Lymphoma
NCT07724847
Recruiting
Multicenter Validation of the 2025 Classification Criteria for Axial Spondyloarthritis
Axial Spondyloarthritis (AxSpA)
NCT07512700 Phase 2
Recruiting
Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia
Acute Monocytic Leukemia
NCT07882641 Phase 1, Phase 2
Recruiting
BEX101 in B-cell Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
NCT06084819 Phase 2
Recruiting
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology